High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy
Bone Marrow Transplant
.
2024 May 9.
doi: 10.1038/s41409-024-02301-7.
Online ahead of print.
Authors
George S Mellgard
1
,
Divaya Bhutani
2
,
Markus Y Mapara
2
,
Mathew S Maurer
3
,
Jai Radhakrishnan
4
,
Suzanne Lentzsch
2
,
Rajshekhar Chakraborty
5
Affiliations
1
Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
2
Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
3
Division of Cardiology, Columbia University Irving Medical Center, New York, NY, USA.
4
Division of Nephrology, Columbia University Irving Medical Center, New York, NY, USA.
5
Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY, USA. rc3360@cumc.columbia.edu.
PMID:
38724598
DOI:
10.1038/s41409-024-02301-7
No abstract available
Publication types
Letter